Plus more pharma news from the Pharmalittle newsletter.

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration.

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

U.S. President Donald Trump's ally and far-right political activist, Laura Loomer, alleged on Sunday that the rehiring of ...

T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...

Dr. Vinay Prasad is back at the FDA less than two weeks after the White House pressed the head of the agency to remove him from his multiple agency leadership roles, an HHS spokesperson said Saturday.

The public deserves to the full story about Dr. Vinay Prasad's temporary resignation and how this might impact regulatory decisions moving forward.